Harvard Bioscience, Inc. (HBIO) Given $9.00 Average Target Price by Analysts

Harvard Bioscience, Inc. (NASDAQ:HBIO) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $9.00 for the company and are forecasting that the company will post $0.04 EPS for the current quarter, according to Zacks. Zacks has also given Harvard Bioscience an industry rank of 179 out of 256 based on the ratings given to its competitors.

A number of equities analysts have issued reports on the company. ValuEngine upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Saturday, April 13th. Zacks Investment Research downgraded Harvard Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Harvard Bioscience in a research report on Monday, February 18th.

In other Harvard Bioscience news, CEO Jeffrey Duchemin sold 6,332 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $4.50, for a total transaction of $28,494.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.40% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Royce & Associates LP raised its holdings in shares of Harvard Bioscience by 8.2% during the fourth quarter. Royce & Associates LP now owns 1,730,200 shares of the medical instruments supplier’s stock valued at $5,502,000 after acquiring an additional 130,500 shares during the last quarter. Alambic Investment Management L.P. raised its holdings in shares of Harvard Bioscience by 415.8% during the fourth quarter. Alambic Investment Management L.P. now owns 135,599 shares of the medical instruments supplier’s stock valued at $431,000 after acquiring an additional 109,312 shares during the last quarter. GSA Capital Partners LLP raised its holdings in shares of Harvard Bioscience by 5.3% during the fourth quarter. GSA Capital Partners LLP now owns 191,657 shares of the medical instruments supplier’s stock valued at $609,000 after acquiring an additional 9,600 shares during the last quarter. Wedge Capital Management L L P NC raised its holdings in shares of Harvard Bioscience by 64.0% during the first quarter. Wedge Capital Management L L P NC now owns 236,095 shares of the medical instruments supplier’s stock valued at $1,018,000 after acquiring an additional 92,152 shares during the last quarter. Finally, Vanguard Group Inc raised its holdings in shares of Harvard Bioscience by 16.3% during the third quarter. Vanguard Group Inc now owns 1,812,401 shares of the medical instruments supplier’s stock valued at $9,515,000 after acquiring an additional 254,493 shares during the last quarter. 74.71% of the stock is owned by institutional investors and hedge funds.

Shares of HBIO stock opened at $2.27 on Wednesday. The company has a market cap of $87.43 million, a price-to-earnings ratio of 19.33 and a beta of 1.33. The company has a current ratio of 2.22, a quick ratio of 1.12 and a debt-to-equity ratio of 0.79. Harvard Bioscience has a 12-month low of $2.12 and a 12-month high of $6.70.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $28.23 million for the quarter, compared to the consensus estimate of $28.50 million. Harvard Bioscience had a positive return on equity of 5.95% and a negative net margin of 1.45%. On average, research analysts predict that Harvard Bioscience will post 0.09 EPS for the current year.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Article: What is a balanced fund?

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.